TELETRADER News
3/7, 6:45 PM (Source: TeleTrader)
more TeleTrader news

Vaccitech hopes Oxford won't halt its $1B IPO plans - report

Vaccitech, a company founded as an Oxford University research spin-off in 2016, is hoping to go public later this year with an initial public offering (IPO) in New York, but Oxford University could be creating some problems for it, the Wall Street Journal reported on Sunday. Oxford Univesity owns some 10% of Vaccitech.

The two sides are at odds over Vaccitech's role in the development of the COVID-19 vaccine developed by Oxford University and AstraZeneca. Vaccitech was created by Sarah Gilbert and Adrian V. S. Hill and it has the exclusive right to using a modified chimpanzee cold virus to trigger immunity in humans, a key part of the COVID-19 shot.

Vaccitech could be valued at up to $1 billion, with investors currently putting its valuation at $700 million.

Breaking the News / VP